Dechra Veterinary Products is pleased to announce the expansion of its range of products to treat otitis externa with the addition of Osurnia following the acquisition of the worldwide rights to the marketing and manufacture of the product from Elanco Animal Health Inc.
Osurnia, a treatment for inflamed or infected canine ears, contains three active ingredients: antibiotic florfenicol, terbinafine, which inhibits the growth of yeast as demonstrated for Malassezia spp., and the glucocorticosteroid, betamethasone acetate, to help relieve discomfort.
It is the same dose for any dog, regardless of size and weight and is easy to administer from a pre-measured, single-dose tube helping to ensure the right dose every time. It also has a flexible, soft tip that is gentle on a dog’s ears.
Osurnia is the latest addition to Dechra’s dermatology range that includes Canaural and Recicort and a range of ear cleaners.
Dechra Country Manager for the UK and ROI, Roddy Webster, said: “We know that otitis externa is a common challenge for both vets and clients with ear infections among the most frequent reasons for dogs to be presented at the vet clinic so we are delighted with the addition of Osurnia, which extends our range of solutions for veterinarians to manage otitis.
“We are now able to offer the best treatment for the pet taking into consideration the veterinarian’s clinical preference and the owner’s lifestyle. Dechra’s experience in otitis will bring a lot of added value to otitis externa management for veterinarians.”
Osurnia is available from veterinary wholesalers. For more information on Dechra’s otitis range, visit the website.